Clarity Pharmaceuticals Ltd.
1.68
AUD
-0.10
(-5.90%)
ISIN
AU0000165375
Return %
Stock
S&P 500
1Y
-65.10
14.20
3Y
64.71
81.12
5Y
48.67
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Michelle Parker
- Full Time Employees
- 100
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- National Innovation Centre Eveleigh NSW Australia 2015
- IPO Date
- Aug 25, 2021
- Website
- claritypharmaceuticals.com
- Similar Companies
- Business
- Clarity Pharmaceuticals Ltd (ASX:CU6) is an Australia-based clinical-stage radiopharmaceutical company that develops next-generation theranostic products for oncology using its proprietary SAR Technology platform, which leverages copper isotopes copper-64 for imaging and copper-67 for therapy to enable superior imaging, therapeutic efficacy, and logistical advantages. The company's core products include SAR-bisPSMA, a lead theranostic for prostate-specific membrane antigen (PSMA)-positive cancers such as metastatic castration-resistant prostate cancer; SAR-Bombesin, a pan-cancer theranostic targeting gastrin-releasing peptide receptors in prostate, breast, ovarian, urinary, small cell lung cancers, glioblastoma, and gastrointestinal stromal tumors; and SARTATE, a theranostic for somatostatin receptor 2 (SSTR2)-expressing neuroendocrine tumors and neuroblastoma; with ongoing clinical development across seven trials in Australia and the United States, a discovery program for additional indications, and a robust intellectual property portfolio. Founded in 2010 and headquartered at the National Innovation Centre in Sydney, Australia, Clarity targets adult and pediatric oncology patients globally through its Targeted Copper Theranostics (TCT) approach. Recent developments include the successful completion of a A$203 million institutional placement in July 2025 at a premium to recent trading prices, bolstering its pro-forma cash balance to approximately A$288 million to fund pivotal Phase 3 trials, therapeutic pipeline advancement, manufacturing expansion, and commercial team growth; initiation of a second Phase 3 trial for 64Cu-SAR-bisPSMA prostate cancer diagnostic following regulatory feedback; promotion of Michelle Parker to CEO; receipt of a third U.S. FDA Fast Track Designation for Cu-67 SAR-bisPSMA in PSMA-positive metastatic castration-resistant prostate cancer; positive Co-PSMA trial results demonstrating superior lesion detection; and a prior A$121 million equity raise in 2024 supporting clinical and manufacturing progress.
Company News
Co-PSMA: Cu-64 SAR-bisPSMA more than doubled prostate cancer lesion and patient detection vs. Ga-68 PSMA-11 in head-to-head trial
Co-PSMA abstract accepted for oral presentation at EAU Annual Congress 2026